Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06821061 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
A Phase 1 study of Influenza and COVID-19 (Coronavirus Disease 2019), sponsored by BioNTech SE.
- Completed
- Registry status
- Phase 1
- Development phase
- 2,650
- Enrollment target
- 20
- Study locations
NCT06821061: Completed Phase 1 study of Influenza and COVID-19 (Coronavirus Disease 2019), sponsored by BioNTech SE.
NCT06821061 is a Phase 1 study of Influenza and COVID-19 (Coronavirus Disease 2019) that has completed, run by BioNTech SE. The registered enrollment target is 2,650 participants, below the 36,787-participant average among 156 other Influenza trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06821061, a Phase 1 study of Influenza and COVID-19 (Coronavirus Disease 2019), has completed, sponsored by BioNTech SE.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2,650 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
Conditions Studied
Interventions
- BIOLOGICAL Investigational Influenza Vaccine
- BIOLOGICAL Investigational COVID-19 Vaccine
- COMBINATION_PRODUCT Investigational Influenza and COVID-19 Combination Vaccine
- BIOLOGICAL Licensed Influenza Vaccine 1
- BIOLOGICAL Licensed Influenza Vaccine 2
Study Locations (20)
California
- Anaheim Clinical Trials, LLC - Anaheim
- Orange County Research Center - Lake Forest
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
- Diablo Clinical Research, Inc. - Walnut Creek
Florida
- Alliance for Multispecialty Research, LLC - Doral
- Indago Research & Health Center, Inc - Hialeah
- Miami Dade Medical Research Institute, LLC - Miami
- Palm Springs Community Health Center - Miami Lakes
New York
- Upstate Global Health Institute - East Syracuse
- University of Rochester Medical Center - Rochester
Connecticut
- Clinical Research Consulting - Milford
Georgia
- Clinical Research Atlanta - Stockbridge
Hawaii
- East-West Medical Research Institute - Honolulu
Missouri
- Clinical Research Professionals - Chesterfield
Nevada
- Las Vegas Clinical Trials - North Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,650 participants |
| Start Date | 2025-02-10 |
| Est. Completion | 2025-12-17 |
| Phase | Phase 1 |
What the finished NCT06821061 record still lists
NCT06821061 is an interventional study that assigns participants to a tested intervention. Its 2,650 participants enrollment target places it among the larger protocols in the corpus, below the 36,787-participant average among 156 other Influenza trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Influenza appearing as the primary indexed condition, and to 5 interventions - of which Investigational Influenza Vaccine is the first listed.
NCT06821061 names 20 study sites across 12 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06821061 about?
NCT06821061 is a clinical study titled "A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People". The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. P...
What is the current status of trial NCT06821061?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2,650 participants. The study started on 2025-02-10. Estimated completion is 2025-12-17.
What conditions does trial NCT06821061 study?
This clinical trial studies the following conditions: Influenza, COVID-19 (Coronavirus Disease 2019).
What interventions are being tested in trial NCT06821061?
The interventions under investigation include: Investigational Influenza Vaccine (BIOLOGICAL), Investigational COVID-19 Vaccine (BIOLOGICAL), Investigational Influenza and COVID-19 Combination Vaccine (COMBINATION_PRODUCT), Licensed Influenza Vaccine 1 (BIOLOGICAL), Licensed Influenza Vaccine 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06821061?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06821061 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06821061's enrollment target sits among peer trials
2,650 24th of 156 higher than 133 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06825715 · 2,653 participants · NA
Multilevel Intervention for Precision Oncology
- NCT06455085 · 2,634 participants · NA
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
- NCT05471908 · 2,674 participants · NA
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
- NCT05111925 · 2,690 participants
Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI